Literature DB >> 7209379

Sclerosing cholangitis in ulcerative colitis.

E Schrumpf, K Elgjo, O Fausa, E Gjone, F Kolmannskog, S Ritland.   

Abstract

In a 5-year period 48 (14%) of 336 patients with ulcerative colitis were found to have hepatobiliary disease. The bile ducts were examined in 35 of these patients, and optimal visualization of both intra- and extra-hepatic bile ducts was obtained in 26. Duct changes compatible with sclerosing cholangitis were found in 14 patients. This finding of sclerosing cholangitis in 4% of all patients admitted with ulcerative colitis by far exceeds previous estimations on the incidence of sclerosing cholangitis in ulcerative colitis. The entire colon was usually affected, and the symptoms of the bowel disease were most often mild or moderate. The age at the onset of the colitis was usually below 20 years in patients with combined ulcerative colitis and hepatobiliary disease. In most patients the hepatobiliary disease gave no symptoms. Biochemical data and the histological findings in the liver biopsies did not distinguish between patients with hepatobiliary disease with and without sclerosing cholangitis. Our follow-up study has so far shown that most patients with sclerosing cholangitis remain asymptomatic for a considerable period of time.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7209379     DOI: 10.3109/00365528009181516

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  33 in total

Review 1.  Distinctive diffuse duodenitis associated with ulcerative colitis.

Authors:  H Mitomi; E Atari; H Uesugi; Y Nishiyama; M Igarashi; N Arai; A Ihara; I Okayasu
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

Review 2.  Controversies in the management of primary sclerosing cholangitis.

Authors:  Jeremy S Nayagam; Stephen P Pereira; John Devlin; Phillip M Harrison; Deepak Joshi
Journal:  World J Hepatol       Date:  2016-02-18

3.  Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab.

Authors:  Ileana Duca; Patricia Ramírez de la Piscina; Silvia Estrada; Rosario Calderón; Katerina Spicakova; Leire Urtasun; Carlos Marra-López; Salvador Zabaleta; Raquel Bengoa; María Asunción Marcaide; Francisco García-Campos
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

4.  Sonographic detection of perihepatic lymphadenopathy is an indicator for primary sclerosing cholangitis in patients with inflammatory bowel disease.

Authors:  Tim O Hirche; Jan Russler; Barbara Braden; Gudrun Schuessler; Stefan Zeuzem; Till Wehrmann; Hans Seifert; Christoph F Dietrich
Journal:  Int J Colorectal Dis       Date:  2004-04-15       Impact factor: 2.571

Review 5.  Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis.

Authors:  G V Papatheodoridis; M Hamilton; P K Mistry; B Davidson; K Rolles; A K Burroughs
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

Review 6.  Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease.

Authors:  Rebecca Saich; Roger Chapman
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

7.  Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm.

Authors:  U Broomé; H Glaumann; G Hellers; B Nilsson; J Sörstad; R Hultcrantz
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

8.  Experimental colitis in rats induces low-grade endotoxinemia without hepatobiliary abnormalities.

Authors:  H S Brand; M A Maas; A Bosma; R J Van Ketel; P Speelman; R A Chamuleau
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

9.  Therapeutic investigations in primary sclerosing cholangitis.

Authors:  R Grijm; K Huibregtse; J Bartelsman; E M Mathus-Vliegen; W Dekker; G N Tytgat
Journal:  Dig Dis Sci       Date:  1986-08       Impact factor: 3.199

10.  Liver histology and follow up of 68 patients with ulcerative colitis and normal liver function tests.

Authors:  U Broomé; H Glaumann; R Hultcrantz
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.